152 results
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
, whether in the CNS or in muscle, eventually leads to loss of function and ultimately cell death. Prior preclinical studies indicate that this platform has … of function and ultimately cell death. Prior preclinical studies indicate that this platform has the potential to prevent mutant protein aggregation
8-K
EX-99.2
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
studies measuring time to tracheostomy or death. Neither study showed a statistically significant difference in mortality at the end of the study . https
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
analyses. SLS-005 was generally well-tolerated and comparable to placebo in safety. There was an imbalance of deaths/death equivalents observed
424B3
i68hit3
15 Mar 24
Prospectus supplement
4:15pm
424B5
ihfgty3
30 Jan 24
Prospectus supplement for primary offering
6:05am
424B5
uuop5k7zmxi8dm7
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
0mtrjz b4iq9vltoulr
28 Nov 23
Prospectus supplement for primary offering
4:06pm
424B3
kh4t bwv85muou19posx
29 Sep 23
Prospectus supplement
4:56pm
424B5
12x24cq 3l6l9
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
EX-99.2
yiw4vsiflukk0i738eh8
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am